AbbVie Sees Solid Japan Outlook Despite 2020 Dip

Multi-Indication Pipeline

 
• By Ian Haydock
  
rheumatoidarthritisknee
RA To Continue As A Pillar For AbbVie In Japan Despite Humira Challenges • Source: Alamy

More from Japan

More from Focus On Asia